Nobilis CAV P4 Data Sheet
Presentation
Freeze-dried vaccine for reconstitution with the solvent provided. Each dose of vaccine contains ≥ 3 log10 TCID50 live attenuated Chicken Anaemia Virus (strain 26P4).
Uses
For active immunisation of broiler breeders to stimulate the production of antibodies to chicken anaemia virus in order to reduce mortality and clinical signs due to chicken anaemia virus in progeny produced during the laying period after vaccination.
Immunity has been demonstrated 6 weeks after vaccination.
Antibody at a level which has been shown to prevent excretion of challenge virus has been demonstrated for at least 10 weeks after vaccination under controlled laboratory conditions.
There is some limited evidence from use in the field that the duration of immunity may be longer, possibly up to 42 weeks.
Dosage and Administration
Reconstitute the vaccine using the diluent provided, allowing 0.2 ml diluent per dose i.e. 200 ml per 1000 doses. Administer 0.2 ml to every bird by intramuscular or subcutaneous injection. Equipment used for vaccination should be sterile and contain no traces of detergents or disinfectants.
Vaccination programme
The optimum age and route of vaccination depend on the local situation and should be determined by the site veterinarian. The chicks should be at least 6 weeks of age before vaccination, and should be vaccinated at least 6 weeks before the expected onset of lay.
Contra-indications, warnings etc.
Do not use in unhealthy birds. Sick or weak birds will not develop adequate immunity following vaccination.
Do not vaccinate birds below 6 weeks of age under any circumstances.
Do not vaccinate birds in the last six weeks before lay or birds in lay.
Do not use in multi-age sites.
The CAA vaccine virus has the ability to spread from vaccinates to susceptible birds. Care should be taken to avoid spread to very young birds and birds in lay.
No clinical signs have been associated with an overdose of the vaccine.
No information is available on the compatibility of this vaccine with any other. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.
Do not mix with any other medicinal product apart from the solvent provided.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress. Under certain conditions, for example extreme disease pressure and variant challenge, fully immune birds may succumb to disease. Therefore, successful vaccination may not be synonymous with full protection in the face of a disease challenge.
Operator warning
Wash and disinfect hands and equipment after vaccinating.
Withdrawal period
Zero days.
For animal treatment only. Keep out of the reach and sight of children.
Pharmaceutical Precautions
Vaccine: Store between +2°C and +8°C. Do not freeze. Protect from light.
Solvent: Do not store above +25°C. Do not freeze. Protect from light.
Once reconstituted the vaccine should be used within 2 hours.
Disposal advice
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
Legal Category:
POM-V
Package quantities
Vaccine: Cardboard box containing 1 or 10 vials of 500 or 1000 doses.
Solvent (Dilavia): Cardboard box containing 10 vials of solvent (100 or 200 ml) respectively.
Not all pack sizes may be marketed.
Further information
Nil.
Marketing authorisation number:
Vm 01708/4322
